Actively Recruiting

Early Phase 1
Age: 18Years - 45Years
All Genders
Healthy Volunteers
NCT05203965

Functional Neuroimaging of Alcoholism Vulnerability: Probing Glutamate and Reward, Using the mGluR5 Inhibitor Mavoglurant

Led by Yale University · Updated on 2025-10-09

80

Participants Needed

1

Research Sites

219 weeks

Total Duration

On this page

Sponsors

Y

Yale University

Lead Sponsor

N

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Collaborating Sponsor

AI-Summary

What this Trial Is About

The purpose of this study is to evaluate the role of Mavoglurant in clarifying the neurobiology of alcoholism risk. This is a one-site, randomized, within subjects, counterbalanced double-blind study of a single dose (200mg) of Mavoglurant and placebo.

CONDITIONS

Official Title

Functional Neuroimaging of Alcoholism Vulnerability: Probing Glutamate and Reward, Using the mGluR5 Inhibitor Mavoglurant

Who Can Participate

Age: 18Years - 45Years
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Ages 18-45 years
  • Estimated full-scale IQ greater than 70
  • Ability to cooperate with all study procedures
  • No history of neurological disorders such as epilepsy
  • No major medical conditions like cancer
  • No history of significant head trauma
  • Stable medication treatment for at least 6 weeks before enrollment
  • Negative urine drug and breath alcohol tests at the time of MRI scan
  • Negative urine pregnancy test at the time of MRI scan
  • No MRI contraindications such as in-body metal implants or severe claustrophobia
  • No contraindications to the study drug
Not Eligible

You will not qualify if you...

  • Any diagnosis of psychotic disorders or current mood or anxiety disorders
  • Severe alcohol use disorder or current substance use disorder (mild or moderate alcohol use disorder allowed if no craving, tolerance, or withdrawal in past 3 months)
  • Psychotic disorder reported in a first-degree relative
  • Auditory or visual impairments that interfere with test-taking
  • Prenatal alcohol exposure plus current features of fetal alcohol syndrome
  • Not fluent in English or primarily educated in a non-English language beyond grade 1
  • Intellectual disability with full-scale IQ below 70
  • Traumatic brain injury with loss of consciousness over 30 minutes or concussion in past 30 days
  • History of neurosurgery or neurologic illness affecting brain function including epilepsy or multiple sclerosis
  • Major medical conditions such as cancer or heart failure
  • Current pregnancy or not using effective birth control to prevent drug exposure to fetus
  • Current substance use except marijuana if last use was more than 24 hours before visit
  • Inability to understand consent or cooperate with study procedures
  • MRI exclusions including metal devices, clips, or fragments in the body

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Hartford Hospital

Hartford, Connecticut, United States, 06106

Actively Recruiting

Loading map...

Research Team

G

Godfrey D Pearlson, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

CROSSOVER

Primary Purpose

PREVENTION

Number of Arms

4

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here